Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
Abstract

Reference Costs are the average cost to the NHS of providing a defined service in a given financial year. The document gives details on how and on what NHS expenditure was used for each financial year. Reference costs index publication is the richest source of financial data on the NHS ever produced. As in previous years, its main purpose is to provide a basis for comparison within (and outside) the NHS between organisations, and down to the level of individual treatments. Reference costs publication shows details of unit cost, average length of stay and activity levels for a wide range of services, No. of episodes, attendances, beddays related to average and range of unit costs.

Main Topics/Subject Category
Expenditure, costs
Variables

NHS expenditure, unit cost, average length of stay and activity levels for a wide range of services, episodes, attendances, bed days.

Keywords
Elective inpatient, non elective inpatient, consultant, face to face contact, non face to face contact, accident and emergency, audiology, audiological services, drugs, palliative care, community nursing service, community, mental health, travel cost, expenditure, treatment
Identifier Variables
HRG
Economic/Subject Categories
Expenditure
Area of Health System
Primary care, Secondary care
Data Available
Risk behaviours, Socio-economic, Demographic
Data collecting organization (s)
Department of Health
Data Type
Administrative
National/Regional
National
Coverage (date of field work)
1998, 1999, 2000, 2001, 2002, 2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010
Unit of Analysis
Aggregate
Sample

All NHS expenditure

Availability
Department of Health
Conditions of Access
Free access
Link
http://www.dh.gov.uk/[…]/
Contact
Tel: 02072104850
Publications
Raftery J, et al. Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness. Br J Ophthalmol 2007; 91: 1244-1246